J Neurosci. 2003 Oct 15;23(28):9418-27.

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM.

Source

Geriatric Research Education and Clinical Center, Bedford Veterans Affairs Medical Center, Bedford, Massachusetts 01730, USA. rjferr@bu.edu

Abstract

The precise cause of neuronal death in Huntington's disease (HD) is unknown. Although no single specific protein-protein interaction of mutant huntingtin has emerged as the pathologic trigger, transcriptional dysfunction may contribute to the neurodegeneration observed in HD. Pharmacological treatment using the histone deacetylase inhibitor sodium butyrate to modulate transcription significantly extended survival in a dose-dependent manner, improved body weight and motor performance, and delayed the neuropathological sequelae in the R6/2 transgenic mouse model of HD. Sodium butyrate also increased histone and Specificity protein-1 acetylation and protected against 3-nitropropionic acid neurotoxicity. Microarray analysis showed increased expression of alpha- and beta-globins and MAP kinase phosphatase-1 in sodium butyrate-treated R6/2 mice, indicative of improved oxidative phosphorylation and transcriptional regulation. These findings strengthen the hypothesis that transcriptional dysfunction plays a role in the pathogenesis of HD and suggest that therapies aimed at modulating transcription may target early pathological events and provide clinical benefits to HD patients.

PMID:: 14561870; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous

Mouse Genome Informatics (MGI)

Supplemental Content

Related citations

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. [Proc Natl Acad Sci U S A. 2008]
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, et al. Proc Natl Acad Sci U S A. 2008 Oct 7; 105(40):15564-9. Epub 2008 Sep 30.
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. [Proc Natl Acad Sci U S A. 2006]
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ. Proc Natl Acad Sci U S A. 2006 Dec 12; 103(50):19176-81. Epub 2006 Dec 1.
Modulation of nucleosome dynamics in Huntington's disease. [Hum Mol Genet. 2007]
Modulation of nucleosome dynamics in Huntington's disease.
Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, et al. Hum Mol Genet. 2007 May 15; 16(10):1164-75. Epub 2007 Apr 2.
Review Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). [Curr Alzheimer Res. 2006]
Review Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G, Cha JH. Curr Alzheimer Res. 2006 Sep; 3(4):403-8.
Review Mechanisms of disease: Histone modifications in Huntington's disease. [Nat Clin Pract Neurol. 2006]
Review Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G, Cha JH. Nat Clin Pract Neurol. 2006 Jun; 2(6):330-8.

See reviews... See all...

Cited by 75 PubMed Central articles

The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology. [Curr Trends Neurol. 2011]
The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology.
Schulte J, Littleton JT. Curr Trends Neurol. 2011 Jan 1; 5:65-78.
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. [PLoS One. 2011]
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. PLoS One. 2011; 6(11):e27746. Epub 2011 Nov 28.
Huntington's Disease and Striatal Signaling. [Front Neuroanat. 2011]
Huntington's Disease and Striatal Signaling.
Roze E, Cahill E, Martin E, Bonnet C, Vanhoutte P, Betuing S, Caboche J. Front Neuroanat. 2011; 5:55. Epub 2011 Aug 23.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the n...
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
J Neurosci. 2003 Oct 15 ;23(28):9418-27.

PubMed
Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of...
Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.
Hum Mol Genet. 2004 Jun 1 ;13(11):1183-92. Epub 2004 Apr 21 .

PubMed
Butyrate from bacterial fermentation of germinated barley foodstuff preserves in...
Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model.
J Gastroenterol Hepatol. 1999 Sep ;14(9):880-8.

PubMed
Oral butyrate for mildly to moderately active Crohn's disease.
Oral butyrate for mildly to moderately active Crohn's disease.
Aliment Pharmacol Ther. 2005 Nov 1 ;22(9):789-94.

PubMed
Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenot...
Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA.
J Biol Chem. 2006 May 5 ;281(18):12580-6. Epub 2005 Dec 28 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: